Document is current
Any future updates will be listed below
-
Authors
Ossenkoppele, Rik https://orcid.org/0000-0003-1584-7477
Reimand, Juhan
Smith, Ruben
Leuzy, Antoine
Strandberg, Olof
Palmqvist, Sebastian https://orcid.org/0000-0002-9267-1930
Stomrud, Erik
Zetterberg, Henrik
,
Scheltens, Philip https://orcid.org/0000-0002-1046-6408
Dage, Jeffrey L https://orcid.org/0000-0002-2192-1699
Bouwman, Femke
Blennow, Kaj https://orcid.org/0000-0002-1890-4193
Mattsson‐Carlgren, Niklas https://orcid.org/0000-0002-8885-7724
Janelidze, Shorena
Hansson, Oskar https://orcid.org/0000-0001-8467-7286
-
Funding
Funding for this research was provided by:
H2020 European Research Council (949570)
Knut och Alice Wallenbergs Stiftelse (2017‐0383)
Marianne and Marcus Wallenberg Foundation (2015.0125)
Parkinsonfonden (1280/20)
Vetenskapsrådet ((2016‐00906)
- License Information
-
More Information
Article History
Received: 19 April 2021
Revised: 15 June 2021
Accepted: 16 June 2021
First Online: 13 July 2021
Conflict of interest
: HZ has served at scientific advisory boards for Eisai, Denali, Roche Diagnostics, Wave, Samumed, Siemens Healthineers, Pinteon Therapeutics, Nervgen, AZTherapies and CogRx, has given lectures in symposia sponsored by Cellectricon, Fujirebio, Alzecure and Biogen, and is a co‐founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program. KB has served as a consultant, at advisory boards, or at data monitoring committees for Abcam, Axon, Biogen, JOMDD/Shimadzu. Julius Clinical, Lilly, MagQu, Novartis, Roche Diagnostics and Siemens Healthineers, and is a co‐founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program. SP has served at scientific advisory boards for Roche and Geras Solutions. JLD is an employee and shareholder of Eli Lilly and Company. OH has acquired research support (for the institution) from AVID Radiopharmaceuticals, Biogen, Eli Lilly, Eisai, GE Healthcare, Pfizer and Roche. In the past 2 years, he has received consultancy/speaker fees from AC Immune, Alzpath, Biogen, Cerveau and Roche. The other authors report no conflicts of interest.
